Annual reportSep 2026
Sep 2026 · General Updates 2 Sep - 32nd AGM scheduled on 25 September 2026; annual report FY 2025-26 web-link shared.
Source: Nse
Prolife Industries Ltd. (PROLIFE)
SME CapPharma stocks · SME cap · NSE
Prolife Industries Ltd. operates in Intermediates, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals20 Oct 2026 · screener
Latest result01 Jun, 08:55 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags24 Apr 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
74BullishSMA20 +12.9% / mo · MACD − · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 57
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
PROLIFED candles · FIT view+15.1%Latest close ₹79.80 on 2026-10-06
Bar
+0.0%
RSI
54
MACD hist
-0.76
52W pos
50%
2026-10-06O ₹79.80H ₹79.80L ₹79.80C ₹79.80Vol 500 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
PROLIFENifty PharmaNifty 500
- PROLIFE
- +0.3%
- Nifty 500
- -5.3%
- Nifty Pharma
- +2.6%
- Vs Nifty 500
- +5.6 pp
Chart stats
6 Oct 2026- From 52W high
- -51.6%
- 52W range position
- 22%
- ATR (14)
- 3.0%
- Volume vs 20D
- 0.26x
- Avg traded value
- ₹0 Cr
- 20D price channel
- ₹75 - ₹91
₹165
₹56.1 - ₹165
₹2.4
Latest completed session
20-session average
55.7% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · WATCHLIST35
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad0
Revenue -4.4% · PAT -27.4% YoY
Technical
Bullish74
Price trend and sector-relative-strength timing.
Valuation
Legacy model-49.9%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence63
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 31 Mar 2026
Bad · 0/100Rev -4% YoY · PAT -27% YoY · margin expansion
Filed 31 Mar 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹25.8 Cr | -4.4% | -10.4% |
| EBITDA | ₹2 Cr | NDF | -8.4% |
| Operating margin | 7.6% | NDF | +17 bps |
| PAT | ₹2.8 Cr | -27.4% | +85.2% |
| PAT margin | 10.7% | NDF | +553 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 7.69
- P/B
- 0.66
- EV/EBITDA
- 6.49
- Market Cap
- 32.70Cr
Profitability
- ROE
- 8.94%
- ROCE
- 12.20%
- ROA
- 7.81%
- Dividend Y
- 0.39%
Growth (CAGR)
- Revenue 5Y
- -6.00%
- EPS 5Y
- -5.00%
- Revenue 3Y
- -11.00%
- EPS 3Y
- -15.00%
Balance Sheet
- Debt/Equity
- 0.01
- Interest Coverage
- 45.56×
- Altman Z
- 6.84
- Book Value
- 121.00
Cash Flow
- FCF Yield
- 3.12%
- FCF Positive Y
- 7/5
- OCF
- -1.64 Cr
- EPS TTM
- 10.38
Shareholding
- Promoter Hold
- 73.74%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 50%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 54.4-1.7% vs prev
Net Profit
₹ CrLatest: 4.3-9.2% vs prev
Return on Equity
%Latest: 8.6-16.7% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend unclear. RSI 54. Wait for confirmation.
- SMA20 rising (~11.5% over last month) — short-term momentum positive.
- RSI(14) at 54 — sideways, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 23% off 52W high · 42% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation & peers
U-Score 35 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 35 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Deep Value
Fundamental score breakdown
U band · WATCHLISTValuation22/30
Growth2/25
Quality0/20
Balance Sheet13/15
Cash Flow5/10
Piotroski
3/9 (+1)
Penalties
-8
Raw sum
35
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
35/100 · legacy band WATCHLIST
Positive drivers
- FCF yield is supportive at 3.1%.
- Balance sheet contributes 13/15 to the score.
- Valuation contributes 22/30 to the score.
Main drags
- Penalty bucket subtracts 8 points.
- Fair-value margin of safety is negative at -49.9%.
- Quality is weaker at 0/20; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
7.7
PB
0.7
EV/EBITDA
6.5
ROE
8.9%
ROCE
12.2%
FCF Yield
3.1%
Debt/Equity
0.0
MoS
-49.9%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
35
Previous: 35
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
-49.9%
Previous: -49.9%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
35
35
35
35
35
35
35
35
35
35
35
35
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹168.11
+52.5% MoS
Growth-justified P/E
5.1
Growth-justified Value
₹53.25
-49.9% MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
JFLLIFE
SME
JFL Life Sciences Ltd.
Pharmaceuticals
match 137
69
5.0
15.0%
+89%
UNDERVALUED
MEDIORG
SME
Medicamen Organics Ltd.
Pharmaceuticals
match 136
14
—
-13.8%
—
OVERVALUED
SAROJA
SME
Saroja Pharma Industries India Ltd.
Pharmaceuticals
match 134
48
9.8
10.1%
+77%
FAIR VALUE
MONOPHARMA
SME
Mono Pharmacare Ltd.
Pharmaceuticals
match 133
18
21.6
2.3%
-408%
OVERVALUED
SUNREST
SME
Sunrest Lifescience Ltd.
Pharmaceuticals
match 132
68
5.5
15.2%
+91%
UNDERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Prolife Industries Ltd. operates in Intermediates, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 31 Mar 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
63Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 38th percentile of the scored universe and 27th percentile within Pharma. Main check: results consistency is weak at 5/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
0 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
38th percentile
overall median 67 · Pharma: 27th pctile, median 70 · SME: 45th pctile, median 64
Evidence depth
Financial-only
0 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
62
acceptable · profit to cash conversion
Balance sheet
96
strong · leverage and solvency
Discipline
50
watch · capital discipline
Results
5
weak · quarterly consistency
Trust positives
- ▸Promoter holding is 73.7%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 3.2%.
- ▸7 years of positive FCF.
Trust risks
- ▸Operating cash flow is negative at ₹-2 Cr.
- ▸3 latest quarters had PAT decline worse than 25% YoY.
- ▸ROCE trend is -6.9%.
- ▸0/4 latest quarters had positive YoY revenue growth.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Prolife Industries Ltd.
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Annual reportSep 2026
Sep 2026 · Shareholders meeting 31 Aug - 32nd AGM scheduled for 25 September 2026; FY2025-26 annual report circulated.
Source: Nse
Annual report
Annual Report 2026
Source: Nse
Annual report
Annual Report 2025
Source: Nse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.